Marinus Net Cash Flow from Operations from 2010 to 2024

MRNS Stock  USD 8.99  0.14  1.58%   
Check Marinus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marinus main balance sheet or income statement drivers, such as Depreciation And Amortization of 523.5 K, Interest Expense of 17.7 M or Selling General Administrative of 63.5 M, as well as many exotic indicators such as Price To Sales Ratio of 17.91, Dividend Yield of 0.0 or Operating Cycle of 419. Marinus financial statements analysis is a perfect complement when working with Marinus Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Marinus Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Marinus Pharmaceuticals Technical models . Check out the analysis of Marinus Pharmaceuticals Correlation against competitors.
For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.

About Marinus Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Marinus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Marinus Pharmaceuticals investors use historical funamental indicators, such as Marinus Pharmaceuticals's Net Cash Flow from Operations, to determine how well the company is positioned to perform in the future. Although Marinus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Marinus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Marinus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Marinus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Marinus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. Marinus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Marinus Pharmaceuticals is a strong investment it is important to analyze Marinus Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Marinus Pharmaceuticals' future performance. For an informed investment choice regarding Marinus Stock, refer to the following important reports:
Check out the analysis of Marinus Pharmaceuticals Correlation against competitors.
For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Marinus Stock analysis

When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Share Portfolio
Track or share privately all of your investments from the convenience of any device
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Is Marinus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marinus Pharmaceuticals. If investors know Marinus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marinus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.63)
Revenue Per Share
0.577
Quarterly Revenue Growth
0.004
Return On Assets
(0.38)
Return On Equity
(2.13)
The market value of Marinus Pharmaceuticals is measured differently than its book value, which is the value of Marinus that is recorded on the company's balance sheet. Investors also form their own opinion of Marinus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Marinus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marinus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Marinus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marinus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marinus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marinus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.